Immune checkpoint inhibitors (ICIs), including targeting programmed cell death‐1 (PD‐1), programmed cell death ligand 1 (PD‐L1), and cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4), have revolutionized cancer treatment, demonstrating broad applications across multiple tumor types [1]. The gene discussed is CD274; the disease is neoplasm.